ProCE Banner Activity

Retrospective Real-world Study of Nirogacestat in Patients With Desmoid Tumors

Conference Coverage
Slideset

Early real-world experience with nirogacestat in patients with desmoid tumors suggested that early responses could be achieved in most patients at the maximum tolerated dose although frequent dose reductions and holds were needed.

Released: November 26, 2024

Expiration: November 25, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics, Inc.